Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist

PURPOSE: To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). METHODS: In this double-blind, placebo-controlled phase 1 study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogasawara, Akihito, Ogawa, Kei, Ide, Ryosuke, Ikenaga, Yuka, Fukunaga, Chie, Nakayama, Satoshi, Tsuda, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229459/
https://www.ncbi.nlm.nih.gov/pubmed/37060458
http://dx.doi.org/10.1007/s00228-023-03476-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229459/
https://www.ncbi.nlm.nih.gov/pubmed/37060458
http://dx.doi.org/10.1007/s00228-023-03476-6

Ejemplares similares